Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.46 Million SEK | 23.87% |
| 2022 | - SEK | -30.01% |
| 2021 | -11.66 Million SEK | -6969.36% |
| 2020 | 193.97 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.76 Million SEK | -1.43% |
| 2024 Q3 | -927 Thousand SEK | 66.46% |
| 2024 Q1 | -2.72 Million SEK | -14.88% |
| 2023 Q2 | -2.79 Million SEK | 24.4% |
| 2023 FY | - SEK | 23.87% |
| 2023 Q4 | -2.45 Million SEK | 5.87% |
| 2023 Q1 | -3.7 Million SEK | 5.99% |
| 2023 Q3 | -2.6 Million SEK | 6.9% |
| 2022 FY | - SEK | -30.01% |
| 2022 Q4 | -3.93 Million SEK | -12.26% |
| 2022 Q3 | -3.5 Million SEK | 19.27% |
| 2022 Q2 | -4.34 Million SEK | -28.67% |
| 2022 Q1 | -3.37 Million SEK | 5.35% |
| 2021 Q2 | -3.06 Million SEK | -321.73% |
| 2021 FY | - SEK | -6969.36% |
| 2021 Q3 | -4.3 Million SEK | -40.41% |
| 2021 Q4 | -3.56 Million SEK | 17.14% |
| 2021 Q1 | -727 Thousand SEK | 0.0% |
| 2020 Q4 | - SEK | 100.0% |
| 2020 Q2 | - SEK | 100.0% |
| 2020 Q1 | -7000.00 SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q3 | -79 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 96.882% |
| AcouSort AB (publ) | -16.7 Million SEK | 31.336% |
| Active Biotech AB (publ) | -43.88 Million SEK | 73.867% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 27407.793% |
| Amniotics AB (publ) | -27.14 Million SEK | 57.746% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 19.329% |
| BioArctic AB (publ) | 275.38 Million SEK | 104.165% |
| Camurus AB (publ) | 562.54 Million SEK | 102.039% |
| Cantargia AB (publ) | -284.31 Million SEK | 95.966% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 41.422% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 32.869% |
| Genovis AB (publ.) | 64.57 Million SEK | 117.762% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 90.019% |
| Mendus AB (publ) | -97.84 Million SEK | 88.279% |
| Kancera AB (publ) | -61.88 Million SEK | 81.468% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 57.178% |
| LIDDS AB (publ) | -39.67 Million SEK | 71.089% |
| Lipum AB (publ) | -37.11 Million SEK | 69.102% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 5.246% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 136.521% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 573550.0% |
| NextCell Pharma AB | -40.98 Million SEK | 72.017% |
| OncoZenge AB (publ) | 7.26 Million SEK | 257.845% |
| Saniona AB (publ) | -69.69 Million SEK | 83.544% |
| Simris Alg AB (publ) | -22.36 Million SEK | 48.714% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 96.387% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 95.933% |
| Xintela AB (publ) | -53.47 Million SEK | 78.551% |
| Ziccum AB (publ) | -20.34 Million SEK | 43.619% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 69.023% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 93.246% |
| CombiGene AB (publ) | -35.33 Million SEK | 67.543% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 91.857% |
| Intervacc AB (publ) | -68.98 Million SEK | 83.373% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 95.173% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -451.394% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 14.608% |
| Corline Biomedical AB | -1.69 Million SEK | -578.238% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 93.383% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 79.073% |
| Aptahem AB (publ) | -10 Million SEK | -14.584% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 199.307% |
| Fluicell AB (publ) | -25.91 Million SEK | 55.742% |
| Biovica International AB (publ) | -119.5 Million SEK | 90.403% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 72.838% |
| Abliva AB (publ) | -93.6 Million SEK | 87.748% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 96.406% |
| 2cureX AB (publ) | -35.13 Million SEK | 67.358% |
| I-Tech AB | 30.34 Million SEK | 137.795% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.395% |
| Cyxone AB (publ) | -20.41 Million SEK | 43.818% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 88.806% |
| Biosergen AB | 228 Thousand SEK | 5130.263% |
| Nanologica AB (publ) | -62.11 Million SEK | 81.537% |
| SynAct Pharma AB | -222.7 Million SEK | 94.85% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 73.851% |
| BioInvent International AB (publ) | -312.7 Million SEK | 96.332% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 3806.696% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 95.048% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -30.145% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 89.435% |